Rxwire
In the news · 48h FDA 38 Eli Lilly 17 Roche 9 Merck & Co. (MSD) 7 Johnson & Johnson 4 AstraZeneca 3 AbbVie 2 Daiichi Sankyo 2
Approvals & regulatory · first seen 10h ago, updated 10h ago

Awiqli insulin, this time for Lilly, with FDA-cleared Onswik

1 outlet Eli Lilly FDA

Another long-acting insulin has cleared the U.S. FDA’s hurdle, with Eli Lilly and Co.’s Onswik (insulin efsitora alfa-gobe) winning approval for the type 2 diabetes community.

Summary from BioWorld Articles.

Coverage 1 article · 1 outlet

  1. BioWorld Articles
    Awiqli insulin, this time for Lilly, with FDA-cleared Onswik